Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Spinal Cord Ser Cases ; 7(1): 58, 2021 07 13.
Article in English | MEDLINE | ID: covidwho-1309431

ABSTRACT

STUDY DESIGN: Focused literature review. OBJECTIVES: Objective of the study was to perform a literature search and summarise the clinical features and prognosis of persons with spinal cord injury (SCI) infected with COVID-19 from the published articles. SETTING: India. METHODS: PubMed, CENTRAL and MEDLINE were systematically searched using specific keywords. The study assessed 2747 scientific studies involving COVID-19 and SCI for possible inclusion in a meta-analysis of SCI and SARS-COV-2. Studies involving persons with SCI who were tested positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the nasopharyngeal or throat swab polymerase chain reaction were included. RESULTS: Out of 2747 articles, 11 articles (206 participants), including six case reports, were included in this review. Fever was the most frequently observed symptom of COVID-19 infection in the SCI population. C-reactive protein (CRP) and lymphocytopenia were common abnormal laboratory parameters. The most common radiological finding in COVID-19 infection was ground glass opacities in lung fields. Prophylactic/therapeutic anticoagulation was given in a significant number of SCI persons infected with COVID-19. Persons with SCI who were diagnosed early showed good outcomes. CONCLUSIONS: Based on the few studies published on COVID-19 and SCI populations since 2019, this study determined fever, elevated CRP, lymphocytopenia and ground glass opacities, which indicated inflammation, compromised immune response, and lung edema, as the main clinical features of COVID-19 infection in SCI population. Though COVID-19 infection reported an increased number of deaths in few studies, a significant number of SCI populations with positive RT-PCR were treated successfully and discharged at home.


Subject(s)
COVID-19/complications , COVID-19/physiopathology , Spinal Cord Injuries/complications , Spinal Cord Injuries/physiopathology , Humans , Prognosis
2.
Spinal Cord Ser Cases ; 6(1): 87, 2020 09 17.
Article in English | MEDLINE | ID: covidwho-779971

ABSTRACT

INTRODUCTION: Respiratory complications (RC) are a leading cause of death after spinal cord injury (SCI) due to compromised immune function and respiratory muscle weakness. Thus, individuals with SCI are at high risk of developing COVID-19 related RC. Results of a SCI clinical trial showed a supervised respiratory muscle training (RMT) program decreased risk of developing RC. The feasibility of conducting unsupervised RMT is not well documented. Four publications (n = 117) were identified in which unsupervised RMT was performed. Significant improvements in respiratory outcomes were reported in two studies: Maximal Inspiratory and Expiratory Pressure (MIP40% and MEP25%, respectively), Peak Expiratory Flow (PEF9%), seated and supine Forced Vital Capacity (FVC23% and 26%, respectively), and Peak Cough Flow (28%). This review and case report will attempt to show that an inspiratory muscle training (IMT) home exercise program (HEP) is feasible and may prepare the respiratory system for RC associated with COVID-19 in patients with SCI. CASE PRESENTATION: A 23-year-old with tetraplegia (P1), history of mechanical ventilation, and hospitalization for RC, completed 27 IMT HEP sessions in one month. MIP and sustained MIP (SMIP) increased from baseline by 28% and 26.5%, respectively. Expiratory volumes and rates also improved (FVC, FEV1, and PEF: 11.7%, 8.3%, and 14.2%, respectively). DISCUSSION: The effects of COVID-19 on patients with SCI remains inconclusive, but recent literature and the results of this case suggest that unsupervised IMT is feasible and may limit the severity of RC in patients with SCI who contract COVID-19.


Subject(s)
Betacoronavirus , Breathing Exercises/methods , Coronavirus Infections/prevention & control , Inhalation/physiology , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Respiratory Tract Infections/prevention & control , Spinal Cord Injuries/therapy , COVID-19 , Coronavirus Infections/physiopathology , Humans , Male , Pneumonia, Viral/physiopathology , Quadriplegia/complications , Quadriplegia/physiopathology , Quadriplegia/therapy , Respiratory Tract Infections/physiopathology , SARS-CoV-2 , Spinal Cord Injuries/complications , Spinal Cord Injuries/physiopathology , Young Adult
3.
Spinal Cord Ser Cases ; 6(1): 69, 2020 08 04.
Article in English | MEDLINE | ID: covidwho-697068

ABSTRACT

STUDY DESIGN: Observational case-control study. OBJECTIVE: Individuals with spinal cord injury (SCI) develop systemic physiological changes that could increase the risk of severe evolution of coronavirus disease 2019 (COVID-19) and result in atypical clinical features of COVID-19 with possible delay in both diagnosis and treatment. We evaluated differences in clinical features and evolution of COVID-19 between people with SCI and able-bodied individuals. SETTING: The study was conducted in an Italian inpatient rehabilitation referral center for individuals with SCI during the lockdown for the COVID-19 pandemic. METHODS: We compared clinical information between patients with SCI and able-bodied healthcare workers of the same center who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the nasopharyngeal swab polymerase chain reaction. RESULTS: Overall, 15 out of the 25 SCI patients admitted to the center and 17 out of the 69 healthcare workers tested positive for SARS-CoV-2. Patients with SCI exhibited a significantly more advanced age and a higher prevalence of comorbidities. Nevertheless, no significant differences in clinical expression of COVID-19 and treatment strategies were observed between the two groups. All hospitalized subjects were treated in nonintensive care units and no deaths occurred in either group. CONCLUSIONS: This study does not support the supposed notion that COVID-19 could exhibit atypical clinical features or a worse evolution in the frail population of people with SCI.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Anticoagulants/therapeutic use , Antiviral Agents/therapeutic use , Coronavirus Infections/therapy , Hydroxychloroquine/therapeutic use , Oxygen Inhalation Therapy , Pneumonia, Viral/therapy , Spinal Cord Injuries/physiopathology , Adult , Aged , Azithromycin/therapeutic use , Betacoronavirus , COVID-19 , Case-Control Studies , Coronavirus Infections/complications , Coronavirus Infections/drug therapy , Coronavirus Infections/physiopathology , Drug Combinations , Enzyme Inhibitors/therapeutic use , Female , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Italy , Lopinavir/therapeutic use , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/physiopathology , Prognosis , Rehabilitation Centers , Ritonavir/therapeutic use , SARS-CoV-2 , Spinal Cord Injuries/complications , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL